Fate Of Copaxone 40mg Patents Depends On Courts After PTAB Rejection
Executive Summary
Teva awaits district court ruling on patents covering the three-times-a-week dosage and is appealing the Patent Trial & Appeal Board’s findings of unpatentability.
You may also be interested in...
Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations
FDA approves the product well before Mylan's prediction of 2018.
Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations
FDA approves the product well before Mylan's prediction of 2018.
Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February
Teva is seeking injunction to block generic entry after court rules four patents on the three-times-a-week dosage are invalid; analysts expect launch soon after FDA approves an ANDA, with Sandoz/Momenta generic the likely leader.